Defensin peptide–induced LGR6-positive skin stem cell activation

Defensin peptide–induced LGR6-positive skin stem cell activation refers to a novel regenerative pathway in which topical defensins, a class of innate immune antimicrobial peptides, activate quiescent LGR6-positive skin stem cells located in hair follicles or basal epidermis[1][2][3][4][5][6][7]. This activation leads to increased cell turnover, production of new keratinocytes, and enhancement of epidermal structure and function—foundational biological processes implicated in wound healing and skin rejuvenation[1][2][6][7][8]. Topical defensin-containing formulations have been shown to increase epidermal thickness, improve skin viscoelasticity, and reduce the appearance of wrinkles and photoaging, generally without the irritation associated with retinoids[5][6][7]. Defensin signaling differs from traditional wound healing, as it can trigger stem cell activation and skin renewal without visible injury, opening avenues for non-invasive anti-aging therapies[2][3][4][5]. Current clinical application is limited to cosmetic use, with products such as DefenAge utilizing synthetic defensins to target hair follicles and activate the LGR6+ stem cell niche. While well tolerated, defensin-based therapy should be considered investigational for therapeutic use beyond skin rejuvenation, and "skin stem cell activation via defensin peptide signaling" is a pathway or mechanism rather than a single molecular target or druggable receptor[1][2][3][4][5][6][7][8]. Note: - The submitted target is not a single molecular entity but a biological mechanism involving both defensin peptides and the LGR6 receptor on skin stem cells. - The canonical target for drug development would be more accurately described as either "LGR6-positive skin stem cell" or "defensins (antimicrobial peptides)", depending on the context. - There may be ambiguity or "too much information" for the canonical target field, as this describes a pathway, not a standard receptor, enzyme, or protein drug target. - No standard abbreviation exists for this pathway as a therapeutic target.

Other names

Defensin signaling for skin stem cell activationDefensin–LGR6 stem cell pathwayDefensins for skin rejuvenation

Activation of dormant LGR6-positive epithelial stem cells in the skin via defensin signaling[1][2][3][6]; Induction of keratinocyte proliferation and epidermal regeneration[4][8]